Car T Kymriah denied as duplicate or overlapping therapy by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for car t kymriah are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denied Kymriah (Tisagenlecleucel) as Duplicate Therapy

A duplicate-therapy denial for Kymriah (tisagenlecleucel, a CAR-T cell therapy) from UnitedHealthcare is unusual and almost always reflects a data or administrative error rather than a genuine clinical duplication. CAR-T therapies like Kymriah involve a unique, one-time manufacturing process using the patient's own cells; there is no conventional sense in which two CAR-T therapies are "duplicates" of each other, and the therapy cannot simply be re-administered like a repeated drug course. This type of denial requires immediate clarification and, if confirmed as a denial, should be appealed urgently.

## Why It Is Appealable

A duplicate-therapy designation requires UHC to identify a therapeutically equivalent treatment already dispensed or authorized. For a cell therapy with a unique mechanism and a one-time administration profile, that designation is almost impossible to sustain clinically. Additionally:

• ACA §2719 / ERISA §503: Full internal appeal and independent external review are available.
• External review window: Generally four months from the final internal denial notice — verify on your Explanation of Benefits immediately, as CAR-T timelines are clinically urgent.
• Expedited review: Given the life-threatening nature of the cancers for which Kymriah is approved, expedited internal appeal and expedited external review (typically 72 hours) are almost certainly appropriate here.

## Appeal Process and Timeline

1. Contact UHC immediately to determine whether this is a billing/administrative error (e.g., duplicate claim submission) versus a substantive clinical denial. 2. If administrative: Work with the treating facility's billing team to correct the claim — this may resolve without a formal appeal. 3. If a substantive clinical denial: Request the denial in writing with the specific duplicate agent UHC has identified. 4. File an expedited internal appeal attaching documentation that no clinically equivalent CAR-T or other therapy has been previously administered for this episode. 5. Escalate immediately to expedited external review if the internal appeal is denied or if the timeline is clinically urgent.

## Documentation to Gather

• Full treatment history: A complete record of all prior oncologic therapies, confirming no prior CAR-T administration for this diagnosis episode.
• Diagnosis and staging documentation: Pathology, flow cytometry, bone marrow biopsy, and oncology chart notes confirming the current diagnosis and relapse/refractory status.
• Prescriber urgent letter: A statement from the treating oncologist explaining that Kymriah is a unique, one-time cell therapy with no therapeutic duplicate in the patient's current treatment record, and that delay poses immediate clinical risk.
• Facility treatment records: Confirmation from the treating center's medical records that no prior CAR-T infusion has been administered.

## Criteria-Mapping Structure

Obtain Kymriah's FDA-approved prescribing information and UHC's coverage policy. For the duplicate-therapy finding specifically, the mapping is: (1) UHC's duplicate identification vs. (2) the actual treatment record showing no prior equivalent therapy. A direct factual rebuttal is sufficient — and given the clinical stakes, pursue expedited review in parallel with the internal appeal.